Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GCK | P35557 | 9/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711315 | 0.90 | NPC1 (0.47) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3508786 | 0.88 | NPC1 (0.47) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL162235 | 0.88 | NPC1 (0.52) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3647874 | 0.87 | RAB9A (0.48) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3508549 | 0.87 | LMNA (0.47) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3646471 | 0.87 | NPC1 (0.46) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3645339 | 0.86 | RAB9A (0.46) | RAB9ANPC1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL3351202 | 0.85 | NPC1 (0.48) | RAB9ANPC1MEN1KMT2AGCK | |
| SCHEMBL168243 | 0.84 | MEN1 (0.51) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3690562 | 0.81 | NPC1 (0.41) | RAB9ANPC1HPGDSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | RAB9A 3199/4885NPC1 204/4885HPGD 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.